Based on the dual therapeutic potential of VCP inhibition as well as its ability to regulate critical oncogene and tumor suppressor protein levels, we are currently evaluating its therapeutic efficacy in controlling NSCLC metastasis using an intrapulmonary tumor implantation murine model. The gene discussed is VCP; the disease is neoplasm.